Dapagliflozin vs Metformin for Polycystic Ovary Syndrome
Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome
Recruiting
Phase 3
Interventional Study
Polycystic Ovary Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 40
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 70 (estimated)
- Sponsor
- Future University in Egypt · Other
Who this trial is looking for
This trial is looking for women with polycystic ovary syndrome (PCOS) who are between 18 and 39 years old and experiencing infertility. Participants will be treated with either Dapagliflozin or Metformin to see which is more effective.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with polycystic ovary syndrome (PCOS).
- I am between 18 and 39 years old.
- I am experiencing infertility.
You may not be able to join if
- I have a history of diabetes.
- I have liver or kidney problems.
- I have an inflammatory disease or cancer.
- I have had a recent heart event.
- I have used certain medications that affect glucose tolerance.
- I have a known allergy to dapagliflozin or SGLT2 inhibitors.
- I have an eating disorder or gastrointestinal disorder.
- I have had bariatric surgery.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In PCOS (Polycystic Ovary Syndrome), studies have found impaired incretin secretion and activity, particularly in overweight/obese individuals.
Conflicting results exist regarding glucagon-like peptide-1(GLP-1) levels in PCOS patients, with studies reporting reduced, normal, or increased levels. Incretin-based therapy has been suggested as a potential treatment to reverse prediabetes risk by pres…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.
* Age: \>18 \<40 years.
* Infertile women (primary or secondary infertility)
Exclusion Criteria:
* Patients with history of diabetes mellitus (Type 1 or 2).
* Patients with …
Contacts